Lipoproteína de alta densidade (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lipoproteína de alta densidade" in Galician language version.

refsWebsite

Global rank Galician rank

35nih.gov

4^th place

6^th place

23doi.org

2^nd place

7^th place

11web.archive.org

1^st place

9archive.org

6^th place

8^th place

3americanheart.org

low place

6,370^th place

2ahajournals.org

3,608^th place

2,169^th place

2clinchem.org

low place

5,389^th place

2liposcience.com

low place

2ajcn.org

low place

2,691^st place

2jacn.org

low place

2medscape.com

719^th place

690^th place

1oxfordjournals.org

1,389^th place

239^th place

1lipidsonline.org

low place

1cdc.gov

218^th place

235^th place

1mesa-nhlbi.org

low place

1about.com

216^th place

300^th place

1nutrition.org

7,878^th place

1,947^th place

1clevelandclinic.org

4,925^th place

low place

1webmd.com

1,169^th place

841^st place

1mayoclinic.com

3,634^th place

3,250^th place

1books.google.com

3^rd place

12^th place

1nzma.org.nz

low place

1annals.org

low place

6,362^nd place

1npr.org

92^nd place

346^th place

1cholesteroladvice.net

low place

1gsk.com

low place

about.com

heartdisease.about.com

Fogoros, Richard N. (15 September 2009). "Raising Your HDL Levels Increasing the GOOD cholesterol". About.com. Arquivado dende o orixinal o 14 de xullo de 2006. Consultado o 8 October 2009.

ahajournals.org

circ.ahajournals.org

Toth PP (2005). "The "Good Cholesterol" High-Density Lipoprotein". Circulation 111 (5): e89–e91. PMID 15699268. doi:10.1161/01.CIR.0000154555.07002.CA. Consultado o 2 June 2011.
HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men.

ajcn.org

http://www.ajcn.org/content/77/5/1146.full
Mensink RP, Zock PL, Kester AD, Katan MB (2003). "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials". American Journal of Clinical Nutrition 77 (5): 1146–55. PMID 12716665.

americanheart.org

"LDL and HDL Cholesterol: What's Bad and What's Good?". American Heart Association. 2 July 2009. Consultado o 8 October 2009.
"Cholesterol Levels". American Heart Association. Consultado o 14 November 2009.
"What Do My Cholesterol Levels Mean?" (PDF). American Heart Association. September 2007. Consultado o 14 November 2009.

annals.org

Meyers CD, Carr MC, Park S, Brunzell JD (2003). "Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia". Annals of Internal Medicine 139 (12): 996–1002. PMID 14678919. doi:10.7326/0003-4819-139-12-200312160-00009.

archive.org

M.J. Sorrentino (2011). "Non-HDL-Cholesterol". Hyperlipidemia in Primary Care. p. 86–87. ISBN 9781603275026.
Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y (2008). "A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". The Journal of Lipid Research 49 (5): 1130–6. PMID 18223297. doi:10.1194/jlr.D700027-JLR200.
Spate-Douglas T, Keyser RE (1999). "Exercise intensity: its effect on the high-density lipoprotein profile". Archives of physical medicine and rehabilitation 80 (6): 691–5. PMID 10378497. doi:10.1016/S0003-9993(99)90174-0.
Baer DJ, Judd JT, Clevidence BA, Muesing RA, Campbell WS, Brown ED, Taylor PR (2002). "Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet". The American journal of clinical nutrition 75 (3): 593–599. PMID 11864868.
van der Gaag MS, van Tol A, Vermunt SH, Scheek LM, Schaafsma G, Hendriks HF (2001). "Alcohol consumption stimulates early steps in reverse cholesterol transport". Journal of lipid research 42 (12): 2077–2083. PMID 11734581.
Clevidence BA, Reichman ME, Judd JT, Muesing RA, Schatzkin A, Schaefer EJ, Li Z, Jenner J, Brown CC, Sunkin M (1995). "Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study". Arteriosclerosis, thrombosis, and vascular biology 15 (2): 179–184. PMID 7749823. doi:10.1161/01.ATV.15.2.179.
Cuvelier I, Steinmetz J, Mikstacki T, Siest G (1985). "Variations in total phospholipids and high-density lipoprotein phospholipids in plasma from a general population: Reference intervals and influence of xenobiotics". Clinical chemistry 31 (5): 763–766. PMID 3987006.
Penner EA, Buettner H, Mittleman MA (2013). "The impact of marijuana use on glucose, insulin, and insulin resistance among US adults". Am. J. Med. 126 (7): 583–9. PMID 23684393. doi:10.1016/j.amjmed.2013.03.002.
Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C". Current medical research and opinion 20 (8): 1253–68. PMID 15324528. doi:10.1185/030079904125004402.

books.google.com

Thijssen, M.A. and R.P. Mensink. (2005). Fatty Acids and Atherosclerotic Risk. In Arnold von Eckardstein (Ed.) Atherosclerosis: Diet and Drugs. Springer. pp. 171–172. ISBN 978-3-540-22569-0.

cdc.gov

"National Reference System for Cholesterol - Cholesterol Reference Method Laboratory Network - HDL Cholesterol Certification Protocol for Manufacturers" (PDF). CDC. Consultado o 10 November 2013.

cholesteroladvice.net

"When is treatment indicated for high cholesterol level?". Arquivado dende o orixinal o 30 de xullo de 2012. Consultado o 23 de febreiro de 2015.

clevelandclinic.org

my.clevelandclinic.org

"The Power of Fish". The Cleveland Clinic Heart and Vascular Institute. Consultado o 8 October 2009.

clinchem.org

Warnick GR, Nauck M, Rifai N (September 2001). "Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays". Clinical Chemistry 47 (9): 1579–1596. PMID 11514391. Arquivado dende o orixinal o 13 de marzo de 2014. Consultado o 10 November 2013.
Okazaki M, Sasamoto K, Muramatsu T, Hosaki S (1997). "Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC". Clinical Chemistry 43 (10): 1885–90. PMID 9342008. Arquivado dende o orixinal o 24 de xullo de 2008. Consultado o 23 de febreiro de 2015.

doi.org

dx.doi.org

Toth PP (2005). "The "Good Cholesterol" High-Density Lipoprotein". Circulation 111 (5): e89–e91. PMID 15699268. doi:10.1161/01.CIR.0000154555.07002.CA. Consultado o 2 June 2011.
Kwiterovich PO (2000). "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". The American journal of cardiology 86 (12A): 5L–10L. PMID 11374859. doi:10.1016/S0002-9149(00)01461-2.
Ruidavets JB, Ducimetière P, Arveiler D, Amouyel P, Bingham A, Wagner A, Cottel D, Perret B, Ferrières J (January 2002). "Types of alcoholic beverages and blood lipids in a French population". J Epidemiol Community Health 56 (1): 24–8. PMC 1732002. PMID 11801616. doi:10.1136/jech.56.1.24.
Mard-Soltani M, Dayer MR, Shamshirgar-Zadeh A, Ali-Bahar H, Nasirbagheban Z (April 2012). "The Buffering Role of HDL in Balancing the Effects of Hypercoagulable State in Type 2 Diabetes". J Applied sciences 12 (8): 745–52. doi:10.3923/jas.2012.745.752.
Rahilly-Tierney CR, Spiro A, Vokonas P, Gaziano JM (2011). "Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study)". Am J Cardiol 107 (8): 1173–7. PMID 21296318. doi:10.1016/j.amjcard.2010.12.015.
Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002). "Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)". Arch. Intern. Med. 162 (22): 2597–604. PMID 12456232. doi:10.1001/archinte.162.22.2597.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC (2007). "HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events". New England Journal of Medicine 357 (13): 1301–10. PMID 17898099. doi:10.1056/NEJMoa064278.
Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y (2008). "A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". The Journal of Lipid Research 49 (5): 1130–6. PMID 18223297. doi:10.1194/jlr.D700027-JLR200.
Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG (2008). "Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study". Arteriosclerosis, thrombosis, and vascular biology 28 (8): 1556–62. PMC 2581752. PMID 18591462. doi:10.1161/ATVBAHA.108.163998.
Ma Y, Li Y, Chiriboga DE, Olendzki BC, Hebert JR, Li W, Leung K, Hafner AR, Ockene IS (April 2006). "Association between Carbohydrate Intake and Serum Lipids". Journal of the American College of Nutrition 25 (2): 155–163. PMC 1479303. PMID 16582033. doi:10.1080/07315724.2006.10719527. Arquivado dende o orixinal o 15 de xaneiro de 2012. Consultado o 1 September 2012.
Siri-Tarino PW, Sun Q, Hu FB, Krauss RM (2010). "Saturated fat, carbohydrate, and cardiovascular disease". Am. J. Clin. Nutr. 91 (3): 502–9. PMC 2824150. PMID 20089734. doi:10.3945/ajcn.2008.26285.
Spate-Douglas T, Keyser RE (1999). "Exercise intensity: its effect on the high-density lipoprotein profile". Archives of physical medicine and rehabilitation 80 (6): 691–5. PMID 10378497. doi:10.1016/S0003-9993(99)90174-0.
Hausenloy DJ, Yellon DM (June 2008). "Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels". Heart 94 (6): 706–14. PMID 18480348. doi:10.1136/hrt.2007.125401.
Rosanoff A, Seelig MS (October 2004). "Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals". J Am Coll Nutr 23 (5): 501S–505S. PMID 15466951. doi:10.1080/07315724.2004.10719389. Arquivado dende o orixinal o 31 de agosto de 2010. Consultado o 23 de febreiro de 2015. A HMG-CoA redutase é un importante encima no metabolismo do colesterol e lípidos, pero non é o único. As estatinas actúan inhibindo, temporalmente, o encima, nunha relación de resposta á dose mentres que o ión magnesio (Mg²⁺) é unha parte importante dun complexo control e regulación desta importante vía. Ambos baixan o LDL-C, algunhas estatinas poden elevar o HDL-C e baixar os triglicéridos, pero os suplementos de Mg fan ambas as cousas bastante fiablemente.
Soudijn W, van Wijngaarden I, Ijzerman AP (2007). "Nicotinic acid receptor subtypes and their ligands". Medicinal Research Reviews 27 (3): 417–33. PMID 17238156. doi:10.1002/med.20102.
Hendriks HF, Veenstra J, van Tol A, Groener JE, Schaafsma G (1998). "Moderate doses of alcoholic beverages with dinner and postprandial high density lipoprotein composition". Alcohol and alcoholism (Oxford, Oxfordshire) 33 (4): 403–410. PMID 9719399. doi:10.1093/oxfordjournals.alcalc.a008410.
Clevidence BA, Reichman ME, Judd JT, Muesing RA, Schatzkin A, Schaefer EJ, Li Z, Jenner J, Brown CC, Sunkin M (1995). "Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study". Arteriosclerosis, thrombosis, and vascular biology 15 (2): 179–184. PMID 7749823. doi:10.1161/01.ATV.15.2.179.
Brenn T (1986). "The Tromsø heart study: Alcoholic beverages and coronary risk factors". Journal of epidemiology and community health 40 (3): 249–256. PMC 1052533. PMID 3772283. doi:10.1136/jech.40.3.249.
Penner EA, Buettner H, Mittleman MA (2013). "The impact of marijuana use on glucose, insulin, and insulin resistance among US adults". Am. J. Med. 126 (7): 583–9. PMID 23684393. doi:10.1016/j.amjmed.2013.03.002.
Meyers CD, Kamanna VS, Kashyap ML (2004). "Niacin therapy in atherosclerosis". Current Opinion in Lipidology 15 (6): 659–65. PMID 15529025. doi:10.1097/00041433-200412000-00006.
Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C". Current medical research and opinion 20 (8): 1253–68. PMID 15324528. doi:10.1185/030079904125004402.
Drexel, H. (2006). "Reducing risk by raising HDL-cholesterol: the evidence". European Heart Journal Supplements 8: F23. doi:10.1093/eurheartj/sul037.
Meyers CD, Carr MC, Park S, Brunzell JD (2003). "Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia". Annals of Internal Medicine 139 (12): 996–1002. PMID 14678919. doi:10.7326/0003-4819-139-12-200312160-00009.

gsk.com

us.gsk.com

"Copia arquivada" (PDF). Arquivado dende o orixinal (PDF) o 01 de marzo de 2012. Consultado o 23 de febreiro de 2015.

jacn.org

Ma Y, Li Y, Chiriboga DE, Olendzki BC, Hebert JR, Li W, Leung K, Hafner AR, Ockene IS (April 2006). "Association between Carbohydrate Intake and Serum Lipids". Journal of the American College of Nutrition 25 (2): 155–163. PMC 1479303. PMID 16582033. doi:10.1080/07315724.2006.10719527. Arquivado dende o orixinal o 15 de xaneiro de 2012. Consultado o 1 September 2012.
Rosanoff A, Seelig MS (October 2004). "Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals". J Am Coll Nutr 23 (5): 501S–505S. PMID 15466951. doi:10.1080/07315724.2004.10719389. Arquivado dende o orixinal o 31 de agosto de 2010. Consultado o 23 de febreiro de 2015. A HMG-CoA redutase é un importante encima no metabolismo do colesterol e lípidos, pero non é o único. As estatinas actúan inhibindo, temporalmente, o encima, nunha relación de resposta á dose mentres que o ión magnesio (Mg²⁺) é unha parte importante dun complexo control e regulación desta importante vía. Ambos baixan o LDL-C, algunhas estatinas poden elevar o HDL-C e baixar os triglicéridos, pero os suplementos de Mg fan ambas as cousas bastante fiablemente.

lipidsonline.org

Després, Jean-Pierre. "The Atherogenic Triad of New Metabolic Risk Factors: Importance of Waist and Fasting Triglycerides as Screening Tools". Visceral Adipose Tissue and Cardiometabolic Risk: Does It Really Matter? Part 2. Arquivado dende o orixinal o 30 de xuño de 2009. Consultado o 8 October 2009.

liposcience.com

"liposcience.com". Arquivado dende o orixinal o 14 de febreiro de 2010. Consultado o 23 de febreiro de 2015.
"liposcience.com". Arquivado dende o orixinal o 12 de febreiro de 2015. Consultado o 23 de febreiro de 2015.

mayoclinic.com

"Trans fat: Avoid this cholesterol double whammy". Mayo Foundation for Medical Education and Research (MFMER). Consultado o 25 June 2010.

medscape.com

cme.medscape.com

Rader, Daniel J. (2004). "Raising HDL in Clinical Practice". Raising HDL in Clinical Practice: Clinical Strategies to Elevate HDL. Consultado o 8 October 2009.
Brewer, H. Bryan (27 December 2005). "Raising HDL-Cholesterol and Reducing Cardiovascular Risk: An Expert Interview With H. Bryan Brewer, Jr, MD". Consultado o 8 October 2009.

mesa-nhlbi.org

mesa-nhlbi.org

nih.gov

ncbi.nlm.nih.gov

Toth PP (2005). "The "Good Cholesterol" High-Density Lipoprotein". Circulation 111 (5): e89–e91. PMID 15699268. doi:10.1161/01.CIR.0000154555.07002.CA. Consultado o 2 June 2011.
Huang CX, Zhang YL (2013). "The target of regulating the ATP-binding cassette A1 protein (ABCA1): promoting ABCA1-mediated cholesterol efflux in different cells". Curr Pharm Biotechnol 14 (6): 623–31. PMID 24016265.
http://www.ncbi.nlm.nih.gov/pubmed/23059119
Kwiterovich PO (2000). "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". The American journal of cardiology 86 (12A): 5L–10L. PMID 11374859. doi:10.1016/S0002-9149(00)01461-2.
Ruidavets JB, Ducimetière P, Arveiler D, Amouyel P, Bingham A, Wagner A, Cottel D, Perret B, Ferrières J (January 2002). "Types of alcoholic beverages and blood lipids in a French population". J Epidemiol Community Health 56 (1): 24–8. PMC 1732002. PMID 11801616. doi:10.1136/jech.56.1.24.
Rahilly-Tierney CR, Spiro A, Vokonas P, Gaziano JM (2011). "Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study)". Am J Cardiol 107 (8): 1173–7. PMID 21296318. doi:10.1016/j.amjcard.2010.12.015.
Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002). "Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)". Arch. Intern. Med. 162 (22): 2597–604. PMID 12456232. doi:10.1001/archinte.162.22.2597.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC (2007). "HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events". New England Journal of Medicine 357 (13): 1301–10. PMID 17898099. doi:10.1056/NEJMoa064278.
Warnick GR, Nauck M, Rifai N (September 2001). "Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays". Clinical Chemistry 47 (9): 1579–1596. PMID 11514391. Arquivado dende o orixinal o 13 de marzo de 2014. Consultado o 10 November 2013.
Okazaki M, Sasamoto K, Muramatsu T, Hosaki S (1997). "Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC". Clinical Chemistry 43 (10): 1885–90. PMID 9342008. Arquivado dende o orixinal o 24 de xullo de 2008. Consultado o 23 de febreiro de 2015.
Hirano T, Nohtomi K, Koba S, Muroi A, Ito Y (2008). "A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". The Journal of Lipid Research 49 (5): 1130–6. PMID 18223297. doi:10.1194/jlr.D700027-JLR200.
Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG (2008). "Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study". Arteriosclerosis, thrombosis, and vascular biology 28 (8): 1556–62. PMC 2581752. PMID 18591462. doi:10.1161/ATVBAHA.108.163998.
Keene D, Price C, Shun-Shin MJ, Francis DP (Jul 18, 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.". BMJ (Clinical research ed.) 349: g4379. PMID 25038074.
Ma Y, Li Y, Chiriboga DE, Olendzki BC, Hebert JR, Li W, Leung K, Hafner AR, Ockene IS (April 2006). "Association between Carbohydrate Intake and Serum Lipids". Journal of the American College of Nutrition 25 (2): 155–163. PMC 1479303. PMID 16582033. doi:10.1080/07315724.2006.10719527. Arquivado dende o orixinal o 15 de xaneiro de 2012. Consultado o 1 September 2012.
Siri-Tarino PW, Sun Q, Hu FB, Krauss RM (2010). "Saturated fat, carbohydrate, and cardiovascular disease". Am. J. Clin. Nutr. 91 (3): 502–9. PMC 2824150. PMID 20089734. doi:10.3945/ajcn.2008.26285.
Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT (May 2006). "Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia". American Journal of Clinical Nutrition 83 (5): 1025–1031. PMID 16685042. Consultado o 1 September 2012.
Spate-Douglas T, Keyser RE (1999). "Exercise intensity: its effect on the high-density lipoprotein profile". Archives of physical medicine and rehabilitation 80 (6): 691–5. PMID 10378497. doi:10.1016/S0003-9993(99)90174-0.
Hausenloy DJ, Yellon DM (June 2008). "Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels". Heart 94 (6): 706–14. PMID 18480348. doi:10.1136/hrt.2007.125401.
Rosanoff A, Seelig MS (October 2004). "Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals". J Am Coll Nutr 23 (5): 501S–505S. PMID 15466951. doi:10.1080/07315724.2004.10719389. Arquivado dende o orixinal o 31 de agosto de 2010. Consultado o 23 de febreiro de 2015. A HMG-CoA redutase é un importante encima no metabolismo do colesterol e lípidos, pero non é o único. As estatinas actúan inhibindo, temporalmente, o encima, nunha relación de resposta á dose mentres que o ión magnesio (Mg²⁺) é unha parte importante dun complexo control e regulación desta importante vía. Ambos baixan o LDL-C, algunhas estatinas poden elevar o HDL-C e baixar os triglicéridos, pero os suplementos de Mg fan ambas as cousas bastante fiablemente.
Hermansen K, Dinesen B, Hoie LH, Morgenstern E, Gruenwald J (2003). "Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: a literature review". Adv Ther 20 (1): 50–78. PMID 12772818.
Mensink RP, Zock PL, Kester AD, Katan MB (2003). "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials". American Journal of Clinical Nutrition 77 (5): 1146–55. PMID 12716665.
Soudijn W, van Wijngaarden I, Ijzerman AP (2007). "Nicotinic acid receptor subtypes and their ligands". Medicinal Research Reviews 27 (3): 417–33. PMID 17238156. doi:10.1002/med.20102.
Baer DJ, Judd JT, Clevidence BA, Muesing RA, Campbell WS, Brown ED, Taylor PR (2002). "Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet". The American journal of clinical nutrition 75 (3): 593–599. PMID 11864868.
van der Gaag MS, van Tol A, Vermunt SH, Scheek LM, Schaafsma G, Hendriks HF (2001). "Alcohol consumption stimulates early steps in reverse cholesterol transport". Journal of lipid research 42 (12): 2077–2083. PMID 11734581.
Hendriks HF, Veenstra J, van Tol A, Groener JE, Schaafsma G (1998). "Moderate doses of alcoholic beverages with dinner and postprandial high density lipoprotein composition". Alcohol and alcoholism (Oxford, Oxfordshire) 33 (4): 403–410. PMID 9719399. doi:10.1093/oxfordjournals.alcalc.a008410.
Clevidence BA, Reichman ME, Judd JT, Muesing RA, Schatzkin A, Schaefer EJ, Li Z, Jenner J, Brown CC, Sunkin M (1995). "Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study". Arteriosclerosis, thrombosis, and vascular biology 15 (2): 179–184. PMID 7749823. doi:10.1161/01.ATV.15.2.179.
Cuvelier I, Steinmetz J, Mikstacki T, Siest G (1985). "Variations in total phospholipids and high-density lipoprotein phospholipids in plasma from a general population: Reference intervals and influence of xenobiotics". Clinical chemistry 31 (5): 763–766. PMID 3987006.
Brenn T (1986). "The Tromsø heart study: Alcoholic beverages and coronary risk factors". Journal of epidemiology and community health 40 (3): 249–256. PMC 1052533. PMID 3772283. doi:10.1136/jech.40.3.249.
Penner EA, Buettner H, Mittleman MA (2013). "The impact of marijuana use on glucose, insulin, and insulin resistance among US adults". Am. J. Med. 126 (7): 583–9. PMID 23684393. doi:10.1016/j.amjmed.2013.03.002.
Benatar JR, Stewart RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". The New Zealand medical journal 120 (1261): U2706. PMID 17853928. Arquivado dende o orixinal o 06 de xullo de 2009. Consultado o 23 de febreiro de 2015.
Meyers CD, Kamanna VS, Kashyap ML (2004). "Niacin therapy in atherosclerosis". Current Opinion in Lipidology 15 (6): 659–65. PMID 15529025. doi:10.1097/00041433-200412000-00006.
Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C". Current medical research and opinion 20 (8): 1253–68. PMID 15324528. doi:10.1185/030079904125004402.
Meyers CD, Carr MC, Park S, Brunzell JD (2003). "Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia". Annals of Internal Medicine 139 (12): 996–1002. PMID 14678919. doi:10.7326/0003-4819-139-12-200312160-00009.

nih.gov

"NIH stops clinical trial on combination cholesterol treatment". National Institute of Health. National Heart, Lung, and Blood Institute (NHLBI). Consultado o 2 June 2011.

nhlbi.nih.gov

"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary" (PDF). National Heart, Lung, and Blood Institute (NHLBI). National Institutes of Health. May 2001.

npr.org

http://www.npr.org/blogs/health/2011/05/28/136678665/study-boosting-good-cholesterol-with-niacin-did-not-cut-heart-risks?ps=sh_sthdl

nutrition.org

ajcn.nutrition.org

Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT (May 2006). "Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia". American Journal of Clinical Nutrition 83 (5): 1025–1031. PMID 16685042. Consultado o 1 September 2012.

nzma.org.nz

Benatar JR, Stewart RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". The New Zealand medical journal 120 (1261): U2706. PMID 17853928. Arquivado dende o orixinal o 06 de xullo de 2009. Consultado o 23 de febreiro de 2015.

oxfordjournals.org

eurheartjsupp.oxfordjournals.org

Sirtori, Cesare R. (October 2006). "HDL and the progression of atherosclerosis: new insights". European Heart Journal Supplements.

web.archive.org

Després, Jean-Pierre. "The Atherogenic Triad of New Metabolic Risk Factors: Importance of Waist and Fasting Triglycerides as Screening Tools". Visceral Adipose Tissue and Cardiometabolic Risk: Does It Really Matter? Part 2. Arquivado dende o orixinal o 30 de xuño de 2009. Consultado o 8 October 2009.
Warnick GR, Nauck M, Rifai N (September 2001). "Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays". Clinical Chemistry 47 (9): 1579–1596. PMID 11514391. Arquivado dende o orixinal o 13 de marzo de 2014. Consultado o 10 November 2013.
Okazaki M, Sasamoto K, Muramatsu T, Hosaki S (1997). "Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC". Clinical Chemistry 43 (10): 1885–90. PMID 9342008. Arquivado dende o orixinal o 24 de xullo de 2008. Consultado o 23 de febreiro de 2015.
"liposcience.com". Arquivado dende o orixinal o 14 de febreiro de 2010. Consultado o 23 de febreiro de 2015.
"liposcience.com". Arquivado dende o orixinal o 12 de febreiro de 2015. Consultado o 23 de febreiro de 2015.
Fogoros, Richard N. (15 September 2009). "Raising Your HDL Levels Increasing the GOOD cholesterol". About.com. Arquivado dende o orixinal o 14 de xullo de 2006. Consultado o 8 October 2009.
Ma Y, Li Y, Chiriboga DE, Olendzki BC, Hebert JR, Li W, Leung K, Hafner AR, Ockene IS (April 2006). "Association between Carbohydrate Intake and Serum Lipids". Journal of the American College of Nutrition 25 (2): 155–163. PMC 1479303. PMID 16582033. doi:10.1080/07315724.2006.10719527. Arquivado dende o orixinal o 15 de xaneiro de 2012. Consultado o 1 September 2012.
Rosanoff A, Seelig MS (October 2004). "Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals". J Am Coll Nutr 23 (5): 501S–505S. PMID 15466951. doi:10.1080/07315724.2004.10719389. Arquivado dende o orixinal o 31 de agosto de 2010. Consultado o 23 de febreiro de 2015. A HMG-CoA redutase é un importante encima no metabolismo do colesterol e lípidos, pero non é o único. As estatinas actúan inhibindo, temporalmente, o encima, nunha relación de resposta á dose mentres que o ión magnesio (Mg²⁺) é unha parte importante dun complexo control e regulación desta importante vía. Ambos baixan o LDL-C, algunhas estatinas poden elevar o HDL-C e baixar os triglicéridos, pero os suplementos de Mg fan ambas as cousas bastante fiablemente.
Benatar JR, Stewart RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". The New Zealand medical journal 120 (1261): U2706. PMID 17853928. Arquivado dende o orixinal o 06 de xullo de 2009. Consultado o 23 de febreiro de 2015.
"When is treatment indicated for high cholesterol level?". Arquivado dende o orixinal o 30 de xullo de 2012. Consultado o 23 de febreiro de 2015.
"Copia arquivada" (PDF). Arquivado dende o orixinal (PDF) o 01 de marzo de 2012. Consultado o 23 de febreiro de 2015.

webmd.com

"Vitamins and Supplements Lifestyle Guide - Flaxseed". WebMD. Consultado o 12 August 2013.